Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Valion Bio (NASDAQ:VBIO) reported that its subsidiary Velocity Bioworks completed a 200-liter Entolimod production run supporting an ongoing study. Conducted in May–June 2026, the non-GMP run achieved approximately 27% higher productivity than historical manufacturing data. The drug substance met all predefined acceptance criteria for the quality attributes assessed.
Drug product filled in June is supplying the ongoing AFRRI study, fully funded by NIAID/RNCP under an interagency agreement with USU/AFRRI. The run followed a 50-liter run completed in January 2026. Valion expects to apply the findings to planned future manufacturing under current good manufacturing practice standards and continues evaluating strategic alternatives for Velocity Bioworks.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointEntolimod production reached 200 liters in May–June 2026, following a 50-liter run completed in January 2026.
- Moderate pointDrug product filled in June 2026 is supplying the ongoing AFRRI Entolimod study.
- Minor pointManufacturing productivity was approximately 27% higher compared with historical manufacturing data.
- Minor pointDrug substance met all predefined acceptance criteria for the quality attributes assessed.
- Minor pointOngoing Entolimod study is fully funded by NIAID/RNCP under an interagency agreement with USU/AFRRI.
- Minor point. Forward-looking: it has not happened yet and may not happen.Valion plans future CGMP manufacturing for Entolimod and expects to apply lessons from this run.
Negative
- Minor pointThe completed 200-liter run was non-GMP, rather than production under good manufacturing practice standards.
Details
Market Reaction – VBIO
On Nov 17, the day this news came out, the latest delayed price for VBIO is 0.21% above the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $0.53. Relative volume is very high at 4.0x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Production run scale
- 200 liters
- Completed non-GMP Entolimod production run
- Productivity increase
- approximately 27%
- Compared with historical manufacturing data
- Prior production run scale
- 50 liters
- Entolimod production run completed in January 2026
Historical Context
-
AFRRI reported final safety data supporting further Entolimod evaluation for acute radiation syndrome.
-
Entolimod advanced into a fully funded AFRRI therapeutic study after positive safety results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-gmp technical
drug substance technical
drug product technical
cgmp technical
animal rule regulatory
toll-like receptor 5 agonist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN ANTONIO, TX / ACCESS Newswire / November 17, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today reported that its wholly owned subsidiary, Velocity Bioworks, completed a 200-liter non-GMP production run of Entolimod at its San Antonio, Texas facility. The run, conducted from May through June 2026, achieved approximately
Drug product from the run was filled in June and is supplying the Company's ongoing Entolimod study, a study fully funded by the National Institute of Allergy and Infectious Diseases ("NIAID")/Radiation and Nuclear Countermeasures Program (RNCP) under an Interagency Agreement with the Uniformed Services University ("USU")/Armed Forces Radiobiology Research Institute ("AFRRI").
The 200-liter run followed a 50-liter production run completed in January 2026. The 200-liter scale is widely recognized as the pivotal bridge between laboratory innovation and clinical reality in biopharmaceutical manufacturing. This scale represents the transition from benchtop process development to CGMP clinical trial material production.1,2
"This run increased our production scale fourfold while also improving productivity. The resulting drug substance met all of our acceptance criteria, with the process yielding more drug substance per liter of fermentation volume," said Dean Zikria, Interim Chief Executive Officer of Valion. "The material is now supporting our ongoing study with AFRRI. We're reporting these results as part of our commitment to keeping shareholders informed of progress on our lead program."
Entolimod is being developed as a potential medical countermeasure for Acute Radiation Syndrome under the FDA's Animal Rule and has received Fast Track and Orphan Drug designations. The Company expects to apply what it learned from this run as it plans future CGMP manufacturing for Entolimod and continues to evaluate strategic alternatives for Velocity Bioworks.
Sources
1 DDN, The ultimate guide to bioprocessing scale-up and Pharma 4.0, https://www.drugdiscoverynews.com/the-ultimate-guide-to-bioprocessing-scale-up-and-pharma-4-0-17209
2 BioProcess International, Lessons in Bioreactor Scale-Up: Part 1 - Exploring Introductory Principles, https://www.bioprocessintl.com/bioreactors/lessons-in-bioreactor-scale-up-part-1-mdash-exploring-introductory-principles
About Valion Bio, Inc.
Valion Bio, Inc. (NASDAQ:VBIO) is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune dysregulation.
The Company's lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome ("ARS") and has been evaluated in animal models under the U.S. Food and Drug Administration's ("FDA") Animal Rule, which allows the Agency to approve new drugs and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA. Valion holds an exclusive, worldwide license from Statera Biopharma to develop and commercialize Entolimod for ARS, radiation-induced neutropenia, and other indications.
Valion is also advancing Entolasta, a next-generation TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company's pipeline includes potential programs in neutropenia and immune dysfunction.
Valion's wholly owned subsidiary, Velocity Bioworks, is a biologics contract development and manufacturing organization with mammalian and microbial capabilities, focused on increasing manufacturing control, reducing costs, accelerating development timelines and strengthening domestic supply-chain security.
For more information, visit www.valionbio.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements in this press release include, among others, statements regarding: the development and regulatory advancement of Entolimod under the FDA Animal Rule; the timing and outcome of regulatory or government interactions; the Company's ability to advance toward 200-liter CGMP manufacturing; the interest of governments or other entities in stockpiling nuclear exposure countermeasures or other biologic drugs; the initiation, design, timing and outcome of investigator-sponsored studies in neutropenia; the development and potential applications of Entolasta; the ability of the Company to expand the TLR5 platform into oncology supportive care or other indications; and the Company's ability to obtain additional capital and the continued listing of the Company's common stock on the Nasdaq Capital Market. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Valion's actual results to differ from those contained in the forward-looking statements, see Valion's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors"; as well as the Company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Valion undertakes no duty to update such information except as required by applicable law.
Investor and Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@valionbio.com
SOURCE: Valion Bio, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Valion Bio achieve in its 200-liter Entolimod production run?
The run achieved approximately 27% higher productivity compared with historical manufacturing data, and the resulting drug substance met all predefined acceptance criteria for the quality attributes assessed. Velocity Bioworks conducted the non-GMP run from May through June 2026.
What is the FDA Animal Rule pathway for Valion Bio's Entolimod?
The FDA's Animal Rule allows approval based on animal efficacy studies when human clinical trials are not ethical or feasible. Entolimod is being developed under this pathway as a potential medical countermeasure for Acute Radiation Syndrome and has received Fast Track and Orphan Drug designations.